Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Navamedic
Deal Size : $9.3 million
Deal Type : Acquisition
Navamedic ASA: Amended Cash Offer to Acquire Sensidose AB And Acquisition of Shares in Sensidose AB
Details : Through the acquisition, Navamedic will broaden its product portfolio, including Flexilev, containing two active substances, levodopa and carbidopa and to support patients suffering from medical conditions, such as Parkinson's disease.
Product Name : Flexilev
Product Type : Other Small Molecule
Upfront Cash : $9.3 million
April 24, 2023
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Navamedic
Deal Size : $9.3 million
Deal Type : Acquisition
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Navamedic
Deal Size : $7.2 million
Deal Type : Acquisition
Navamedic ASA: Recommended Cash Offer to Acquire Sensidose for Approximately SEK 75 Million
Details : Through the acquisition, Navamedic will broaden its product portfolio and to support patients suffering from medical conditions, such as Parkinson's disease, including Flexilev, containing two active substances, levodopa and carbidopa.
Product Name : Flexilev
Product Type : Other Small Molecule
Upfront Cash : $7.2 million
March 29, 2023
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Navamedic
Deal Size : $7.2 million
Deal Type : Acquisition